Ariane at ASTRO 2025 – San Francisco

/in , , /by

28 September – 1 October 2025
Moscone Centre, San Francisco

Ariane was proud to attend the American Society for Radiation Oncology (ASTRO) Annual Conference 2025, one of the world’s leading gatherings in the field of radiation oncology. Representing Ariane, Mark Davies-Cousins, VP International Sales, was on hand to connect with clinicians and partners from across the globe.

A highlight of the conference was an insightful presentation from Dr. Barbet (Macon & Villeurbanne), who shared a detailed update on the latest results from the OPERA trial, reinforcing the growing clinical evidence for Papillon CXB.

Mark also met with clinicians from New York and Hong Kong, both of whom will soon begin offering Papillon CXB as part of their planned cancer treatment programmes — a clear signal of the continued global expansion of this targeted therapy.

We are delighted to see Papillon CXB gaining momentum internationally and thank all partners and clinicians who continue to support and advocate for this innovative approach to cancer treatment.

For more information on Papillon CXB and its clinical applications, please contact:

Mark Davies-Cousins
VP International Sales
mark.davies@arianemedicalsystems.com

Papillon CXB Training at Clatterbridge Cancer Centre

/in , , /by

24–25 September 2025
The Clatterbridge Cancer Centre, Liverpool

For the 19th consecutive year, the Clatterbridge Cancer Centre in Liverpool proudly hosted its renowned Papillon CXB Training event. This two-day programme brought together clinicians from across the globe, offering both presentations and in-context clinical examples from some of the leading advocates of the Papillon technique.

The event opened with an insightful retrospective from Prof. Arthur Sun Myint, who highlighted the ongoing clinical benefits of CXB and outlined the clear advantages of the treatment moving forward.

We are deeply grateful to all of our professional contributors, who shared invaluable expertise supported by real-world treatment results:

And, of course, to the many clinicians who attended and will soon be delivering Papillon CXB as part of their cancer treatment programmes worldwide.

With another successful year completed, our team now looks ahead to the American Society for Radiation Oncology (ASTRO) Conference in San Francisco from 28 September 2025.

For further information or to discuss Papillon CXB’s clinical applications, please contact:

Mark Davies-Cousins
VP International Sales
mark.davies@arianemedicalsystems.com

SFRO ONCOLOGY CONFERENCE

/in , , /by

17–19 September 2025
Bordeaux, France

Ariane was delighted to attend this year’s SFRO Oncology Conference in Bordeaux, alongside our partners at Clerad.

The conference highlighted a major milestone for the Papillon community. With four new Papillon CXB systems now treating patients and another on the way, France has firmly reclaimed its position as one of the leading countries in the world for the use of Papillon contact brachytherapy. This innovative treatment is increasingly recognised for its impact in rectal cancer, skin cancer, and breast IORT.

Throughout the event, our team engaged with clinicians and specialists to share insights on how Papillon CXB can be integrated into cancer centres, expanding the reach of targeted treatments and improving patient outcomes.

If you would like a full briefing on how Papillon CXB could enhance your cancer treatment programme, please contact:

Mark Davies-Cousins
VP International Sales
mark.davies@arianemedicalsystems.com

UPCOMING EVENTS

/in , /by

Key Up and Coming Events

17-19 September 25
SFRO ONCOLOGY CONFERENCE SFRO – Bordeaux, France

Ariane Business Updates

Papillon CXB Installed at St Barts Centre of Excellence

/in , , , /by

Expanding Access to Advanced Brachytherapy in London

We’re proud to announce the successful installation of the Papillon Contact X-ray Brachytherapy (CXB) system at the prestigious St Barts NHS Trust in London EC1 — marking a significant step forward in the delivery of specialist cancer care.

Located within the West Smithfield Trust, St Barts has now joined a growing network of centres across the UK and internationally offering advanced treatment using Papillon Brachytherapy technology, developed and manufactured by Ariane Medical Systems Ltd in the UK.

This cutting-edge solution provides highly targeted radiation therapy for early-stage rectal and skin cancers, delivering effective treatment with minimal side effects and preserving patient quality of life.

We are proud to support the dedicated clinical teams at St Barts in delivering world-class, patient-focused cancer care and look forward to the positive impact this installation will bring to patients in London and beyond.

To learn more about Papillon CXB and its clinical applications, contact us today.

June 2025

Ariane Event Updates

Ariane & Clerad Unite at SFCO 2025: Advancing Innovation in Breast Cancer Care

/in , , /by

Ariane Medical Systems and Clerad proudly came together for the first time to present a joint showcase at SFCO 2025 in Clermont-Ferrand, France, highlighting the latest in breast cancer treatment technology.

During the conference, we unveiled a powerful trio of innovations:

These cutting-edge technologies form a comprehensive approach to early-stage breast cancer care, enabling accurate detection, surgical margin confirmation, and targeted intra-operative radiotherapy — all designed to improve patient outcomes and streamline the treatment process.

This collaboration demonstrates our shared commitment to advancing cancer care through innovation and integration. We’re excited to continue these conversations and share more developments in the months ahead.

Want to learn more or arrange a demonstration? Contact our team today.

May 2025

A Successful ESRTO 2025 for Ariane Medical – Global Interest Grows in Pallion+

/in , , /by

Following key announcements on our latest technical developments and innovations in radiotherapy, Ariane Medical Systems had an incredibly successful showing at ESRTO 2025.

The event served as a powerful platform to showcase the capabilities of our Pallion+ system, with overwhelmingly positive feedback from clinicians, researchers, and healthcare professionals across the globe. Our presence generated significant interest — and we are now actively following up on a large number of product enquiries from across Europe, the Gulf States, the United States, and beyond.

This strong international response reflects growing recognition of Ariane Medical’s commitment to innovation, clinical precision, and patient-first technology in the radiotherapy space.

As we continue to build on the momentum of ESRTO 2025, we look forward to further collaborations and partnerships that will help bring Pallion+ into more treatment centres worldwide.

📩 For product enquiries or more information, please contact our team

May 2025